Sarepta Therapeutics, Inc. (AB3A.F) Stock Price, News & Chart

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close15.50

Open17.02

Day range—

52-week range12.8221.42

Off day high0.00%

Off 52-week high−20.54%

Volume1.00

Avg. volume (3M)22.00

Market cap1.80B

EPS (TTM)-1.36

Forward P/E-2.97

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)0.38

Shares outstanding105.63M

Short interest—

Earnings dateAug 5, 2026

Analyst target—

Profit margin−6.93%

Related companies

Compare ›

What visitors to Sarepta Therapeutics's page also look at.

Company	Mkt cap	Price	Today
Jazz Pharmaceuticals PLCJ7Z.F	11.90B	183.30	−2.47%
UNITED THERAPEUTICS CORP.(DEL.RUTH.F	21.30B	496.70	+1.33%
Intellia Therapeutics Inc.38I.F	1.41B	10.08	+0.40%
Ultragenyx Pharmaceutical Inc.RUP0.F	1.38B	13.97	−1.20%
ACADIA PHARMACEUTICALS INC.DR6.F	3.04B	17.65	−2.35%

From the 4Search instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All AB3A.F news ›

Defense World·2d agoPositive

Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the…

Markets Daily·3d agoNegative

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Rated “Reduce” by Sell-Side Analysts

Posted by Michael Walen on Oct 18th, 2026 Read Our Latest Research Report on Sarepta Therapeutics Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for…

BioSpace·Oct 14

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Details from the SRP-1003 poster presentation: P-066: Preclinical Evaluation of SRP-1003: An αvβ6 Integrin-Targeting siRNA Platform for Targeted Knockdown of DMPK in Myotonic Dystrophy Type 1 (C. Greer, et al.) SRP-1003 also reduced toxic…

The Globe and Mail·Oct 10Negative

Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Sarepta Therapeutics today and set a price target of $18.00. Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Ultragenyx Pharmaceutical,…

markets.businessinsider.com·Oct 8

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX). In a report released today, Anupam Rama from J.P.…

From articles in the 4Search news index.

In the news

14mentions in 30 days

14with it in the headline

Negativesentiment

Most coverage from

themarketsdaily.com4
news.alphastreet.com2
theglobeandmail.com2
biospace.com1
businesswire.com1

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.